Shimano, K., Grimes, A., Rose, M., Kaicker, S., Shah, S., Briones, M., Gunn, E., Nakano, T., Lebensburger, J., Lambert, M., Lilla, S. F., Jesudas, R., Lee-Miller, C., Thompson, A., Bhat, R., Rifkin-Zenenberg, S., Majumdar, S., Kochhar, M., Crary, S., Hege, K., Rothman, J., Ford, J., Bies, J., Wynn, T., Hsieh, L., Ruiz, M., Dinu, B., Wong, J., Kao, P., Arnold, S., Bennett, C., Despotovic, J., Klaassen, R., Neufeld, E., Neunert, C., London, W., Grace, R. (2025). End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children. Blood. https://doi.org/10.1182/blood-2025-738